We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pharmacogenomics and Pediatric Asthmatic Medications.
- Authors
Lim, Christy; Priefer, Ronny
- Abstract
Asthma is a respiratory condition often stemming from childhood, characterized by difficulty breathing and/or chest tightness. Current treatment options for both adults and children include beta-2 agonists, inhaled corticosteroids (ICS), and leukotriene modifiers (LTM). Despite recommendations by the Global Initiative for Asthma, a substantial number of patients are unresponsive to treatment and unable to control symptoms. Pharmacogenomics have increasingly become the front line of precision medicine, especially with the recent use of candidate gene and genome- wide association studies (GWAS). Screening patients preemptively could likely decrease adverse events and therapeutic failure. However, research in asthma, specifically in pediatrics, has been low. Although numerous adult trials have evaluated the impact of pharmacogenomics and treatment response, the lack of evidence in children has hindered progress towards clinical application. This review aims to discuss the impact of genetic variability and response to asthmatic medications in the pediatric population.
- Subjects
DRUG therapy for asthma; PHARMACOGENOMICS; DRUG receptors; ADRENOCORTICAL hormones; GENETIC variation; TREATMENT effectiveness; DRUGS; INHALATION administration; LEUKOTRIENES; CHILDREN
- Publication
Journal of Respiration (JoR), 2022, Vol 2, Issue 1, p25
- ISSN
2673-527X
- Publication type
Article
- DOI
10.3390/jor2010003